These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 33518623)

  • 21. A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel.
    Goldberg E; Ben Zvi H; Sheena L; Sofer S; Krause I; Sklan EH; Shlomai A
    Clin Microbiol Infect; 2021 Jun; 27(6):917.e1-917.e4. PubMed ID: 33705849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Favipiravir and COVID-19: A Simplified Summary.
    Ghasemnejad-Berenji M; Pashapour S
    Drug Res (Stuttg); 2021 Mar; 71(3):166-170. PubMed ID: 33176367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.
    Lou Y; Liu L; Yao H; Hu X; Su J; Xu K; Luo R; Yang X; He L; Lu X; Zhao Q; Liang T; Qiu Y
    Eur J Pharm Sci; 2021 Feb; 157():105631. PubMed ID: 33115675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.
    Lai CC; Chao CM; Hsueh PR
    J Microbiol Immunol Infect; 2021 Oct; 54(5):767-775. PubMed ID: 34253490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
    Solaymani-Dodaran M; Ghanei M; Bagheri M; Qazvini A; Vahedi E; Hassan Saadat S; Amin Setarehdan S; Ansarifar A; Biganeh H; Mohazzab A; Khalili D; Hosein Ghazale A; Reza Heidari M; Taheri A; Khoramdad M; Mahdi Asadi M; Nazemieh M; Varshochi M; Abbasian S; Bakhtiari A; Mosaed R; Hosseini-Shokouh SJ; Shahrokhi M; Yassin Z; Ali Zohal M; Qaraati M; Rastgoo N; Sami R; Javad Eslami M; Asghari A; Namazi M; Ziaie S; Jafari-Moghaddam R; Kalantari S; Memarian M; Khodadadi J; Hossein Afshari M; Momen-Heravi M; Behzadseresht N; Reza Mobayen A; Mozafari A; Movasaghi F; Haddadzadeh Shoushtari M; Moazen J
    Int Immunopharmacol; 2021 Jun; 95():107522. PubMed ID: 33735712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
    Hassanipour S; Arab-Zozani M; Amani B; Heidarzad F; Fathalipour M; Martinez-de-Hoyo R
    Sci Rep; 2021 May; 11(1):11022. PubMed ID: 34040117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA.
    Delen LA; Gok A; Kasapoglu US; Cagasar O; Gok Z; Berber N; Derya S; Tetik B
    Acta Clin Croat; 2022 Nov; 61(3):403-411. PubMed ID: 37492367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative detection of SARS-CoV-2 RNA in nasopharyngeal samples from infected patients with mild disease.
    Bustos P; Tambley C; Acevedo A; Andrade W; Leal G; Vidal D; Roldán F; Fasce R; Ramírez E
    J Med Virol; 2021 Apr; 93(4):2439-2445. PubMed ID: 33368332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital.
    Sirijatuphat R; Suputtamongkol Y; Angkasekwinai N; Horthongkham N; Chayakulkeeree M; Rattanaumpawan P; Koomanachai P; Assanasen S; Rongrungruang Y; Chierakul N; Ratanarat R; Jitmuang A; Wangchinda W; Kantakamalakul W
    BMC Infect Dis; 2021 Apr; 21(1):382. PubMed ID: 33902480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
    Abdelnabi R; Foo CS; Kaptein SJF; Zhang X; Do TND; Langendries L; Vangeel L; Breuer J; Pang J; Williams R; Vergote V; Heylen E; Leyssen P; Dallmeier K; Coelmont L; Chatterjee AK; Mols R; Augustijns P; De Jonghe S; Jochmans D; Weynand B; Neyts J
    EBioMedicine; 2021 Oct; 72():103595. PubMed ID: 34571361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
    JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Favipiravir use for SARS CoV-2 infection.
    Boretti A
    Pharmacol Rep; 2020 Dec; 72(6):1542-1552. PubMed ID: 33108587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
    Dabbous HM; Abd-Elsalam S; El-Sayed MH; Sherief AF; Ebeid FFS; El Ghafar MSA; Soliman S; Elbahnasawy M; Badawi R; Tageldin MA
    Arch Virol; 2021 Mar; 166(3):949-954. PubMed ID: 33492523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
    Kocayiğit H; Özmen Süner K; Tomak Y; Demir G; Yaylacı S; Dheir H; Güçlü E; Erdem AF
    J Clin Pharm Ther; 2021 Apr; 46(2):454-459. PubMed ID: 33128482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU.
    Çalık Başaran N; Uyaroğlu OA; Telli Dizman G; Özışık L; Şahin TK; Taş Z; İnkaya AÇ; Karahan S; Alp Ş; Alp A; Metan G; Zarakol P; Sain Güven G; Öz ŞG; Topeli A; Uzun Ö; Akova M; Ünal S
    Turk J Med Sci; 2021 Apr; 51(2):411-420. PubMed ID: 32718127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
    Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D;
    Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.
    Dabbous HM; El-Sayed MH; El Assal G; Elghazaly H; Ebeid FFS; Sherief AF; Elgaafary M; Fawzy E; Hassany SM; Riad AR; TagelDin MA
    Sci Rep; 2021 Mar; 11(1):7282. PubMed ID: 33790308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial.
    Carrouel F; Valette M; Gadea E; Esparcieux A; Illes G; Langlois ME; Perrier H; Dussart C; Tramini P; Ribaud M; Bouscambert-Duchamp M; Bourgeois D
    Clin Microbiol Infect; 2021 Oct; 27(10):1494-1501. PubMed ID: 34044151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum.
    Habler K; Brügel M; Teupser D; Liebchen U; Scharf C; Schönermarck U; Vogeser M; Paal M
    J Pharm Biomed Anal; 2021 Mar; 196():113935. PubMed ID: 33548872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
    Yan D; Liu XY; Zhu YN; Huang L; Dan BT; Zhang GJ; Gao YH
    Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32430428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.